Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GRAIL, Inc. (Nasdaq: GRAL) files reports with the U.S. Securities and Exchange Commission that provide detail on its operations as a healthcare diagnostics company focused on multi-cancer early detection. On this page, you can review GRAIL’s SEC filings, including current reports on Form 8-K that describe material events such as private placements, equity distribution agreements, commercial leases, preliminary financial results, and strategic collaboration arrangements.
Recent 8-K filings outline securities purchase agreements for private placements of common stock and pre-funded warrants, a stock purchase agreement with Samsung-related entities tied to a planned business collaboration for commercialization of the Galleri test in Asia, and an equity distribution agreement that allows at-the-market offerings of common stock through designated sales agents. Other filings describe a long-term lease for a new corporate headquarters in Sunnyvale, California and the release of quarterly financial results, along with the company’s use of non-GAAP measures such as Adjusted Gross Profit (Loss) and Adjusted EBITDA.
Through these filings, investors can see how GRAIL structures its financings, the key terms of its strategic agreements, and selected information about its financial condition and operations. Stock Titan’s platform adds AI-powered summaries that explain the main points of each filing in plain language, highlight important sections, and help distinguish between one-time transactions and ongoing obligations. Users can also quickly locate information related to equity issuances, registration rights, and other matters that may affect existing or prospective shareholders.
Grail, Inc. (GRAL): Schedule 13G/A (Amendment No. 2) — CRCM LP and affiliated entities reported beneficial ownership of 1,842,651 shares of Grail common stock, representing 5.11% of the class. The group holds shared voting and dispositive power over 1,842,651 shares and no sole power. Percentages are based on 36,047,799 shares outstanding as of June 30, 2025.
Reporting persons include CRCM Opportunity Funds III & IV, CRCM Institutional Master Fund (BVI), CRCM G SPV, CRCM LP, CRCM LLC, their general partners, and Chun R. Ding. They certified the holdings were not acquired to change or influence control.
Joshua J. Ofman, President of GRAIL, Inc. (GRAL), reported a sale of 9,692 shares of common stock on 10/02/2025 at a reported price of $64.0025 per share. After the transaction he beneficially owns 478,182 shares. The filing notes the sale was executed under a Rule 10b5-1 trading plan adopted on March 13, 2025, and the Form 4 was signed by an attorney-in-fact on 10/03/2025. The report is a routine Section 16 disclosure showing an officer-initiated disposition under an established trading plan.
GRAIL, Inc. (GRAL) filed a Form 144 reporting a proposed sale of 89,237 shares of common stock with an aggregate market value of $5,848,592.98, based on an approximate sale date of 10/06/2025 on NASDAQ. The filing shows the securities were originally acquired on 10/03/2024 upon vesting of restricted stock units under the issuer's equity incentive plans; the acquisition amount reported is 152,810 shares and the stated nature of payment is services rendered with a payment date of 10/03/2025. The filing also discloses two recent sales by Joshua J. Ofman: 4,202 shares sold on 08/19/2025 for $134,548.04 and 9,692 shares sold on 10/02/2025 for $601,485.52. Certain filer identification fields (CIK/CCC and filer contact name) and issuer address details are not provided in the visible content.
GRAIL, Inc. filed a Form 144 disclosing a proposed sale of 9,692 common shares, acquired as restricted stock units on 04/30/2025, with an aggregate market value of $601,485.52. The filing identifies the broker as Morgan Stanley Smith Barney LLC and lists an approximate sale date of 10/02/2025 on NASDAQ. The filing also reports a recent sale by the same person of 4,202 shares on 08/19/2025 for gross proceeds of $134,548.04. The issuer's shares outstanding are listed as 36,047,799. The notice states the seller represents they possess no undisclosed material adverse information and includes the standard Rule 10b5-1 and misstatement warnings.
GRAIL, Inc. has signed a long-term lease for a new corporate headquarters at 250 S. Matilda Avenue in Sunnyvale, California. The company will lease approximately 75,556 rentable square feet from Sunnyvale Office Acquisition, LLC.
The lease is expected to begin on or about October 1, 2026 and run through on or about September 30, 2037. Initial base rent is approximately $449,558 per month, with about 5% annual increases, plus additional costs such as building expenses and taxes.
GRAIL has rights to expand into additional space and may renew the lease for an extra five-year term under specified conditions. The arrangement requires a letter of credit as security and includes customary covenants, representations, obligations and indemnities for both parties.
Joshua J. Ofman, identified as an officer (President) of GRAIL, Inc. (ticker GRAL), reported a sale of common stock on 08/19/2025. The Form 4 shows a transaction code S for the sale of 4,202 shares at a broker-calculated weighted average price of $32.02. After the sale, Ofman beneficially owned 487,874 shares on a direct basis. The filer notes the shares were sold as part of a block trade executed in multiple transactions and offers to provide detailed per-trade pricing on request. The form was signed by an attorney-in-fact on 08/20/2025.
Aaron Freidin, Chief Financial Officer and Director of GRAIL, Inc. (GRAL), reported a sale of 877 shares of GRAIL common stock on 08/19/2025 at a weighted-average price of $32.02 per share. After the reported transactions, he beneficially owns 285,143 shares, held directly. The filing states the sale was executed as a block trade in multiple transactions and that the broker-calculated price is a weighted average; the reporter offers to provide detailed per-trade pricing on request. No derivative transactions were reported.
Form 144 notice for GRAIL, Inc. (GRAL) states that an individual plans to sell 4,511 shares of the issuer's common stock on the NASDAQ with an aggregate market value of $147,964.08, against 36,047,799 shares outstanding. The securities were acquired on 06/28/2024 when 8,076 shares vested from restricted stock units issued by the company; payment was recorded as services rendered. The filer discloses two recent sales by the same person in the past three months: 9,692 shares sold on 06/12/2025 for $410,019.09 and 6,992 shares sold on 06/30/2025 for $503,984. The form includes the required representation that the seller is not aware of undisclosed material adverse information.
GRAIL, Inc. Form 144 discloses a proposed sale under Rule 144 of 952 shares of common stock by the named person, with an aggregate market value of $30,873.36, and an approximate sale date of 08/21/2025 on the NASDAQ. The shares were acquired upon vesting of restricted stock units on 06/28/2024 and were granted as compensation for services. The filing also reports a prior sale by Aaron Freidin of 8,000 shares on 07/15/2025 generating gross proceeds of $311,440. The filer affirms no undisclosed material adverse information is known.
This Schedule 13G/A reports that PRIMECAP MANAGEMENT CO/CA beneficially owns 2,057,089 shares of GRAIL common stock (class reported as COM), representing 5.72% of the outstanding class. The filing discloses sole voting power over 2,027,466 shares and sole dispositive power over 2,057,089 shares.
The statement affirms the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Items identifying group members, subsidiaries and related classifications are marked not applicable, and the filing includes the certification required under Item 10 attesting to the accuracy of the disclosure.